Skip to main content
. 2021 May 31;23(11):1911–1921. doi: 10.1093/neuonc/noab128

Fig. 4.

Fig. 4

Immune-competent hamsters develop an immune response against Delta-24-RGD and hamGSC tumors. (A, B) Flow cytometric analysis of brain-infiltrating lymphocytes (n = 3 hamsters per group) 1 week (A) and 2 weeks (B) after Delta-24-RGD treatment. Data are shown as mean ± SEM, * adjusted P < .05, ** adjusted P < .005, t tests corrected for multiple comparisons using the Holm–Sidak method and α = 0.05. (C) ELISA demonstrating anti-adenovirus antibodies in hamster serum collected 10 days after Delta-24-RGD treatment.